Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141050 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT00141050 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 90 participants.
The verdict
NCT00141050, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
Interventions
- DRUG Focalin XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-05 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141050
The ClinicalTrials.gov registry entry for NCT00141050 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Focalin XR is the first listed.
NCT00141050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141050 about?
NCT00141050 is a clinical study titled "Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD". The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
What is the current status of trial NCT00141050?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2005-05. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00141050?
The interventions under investigation include: Focalin XR (DRUG).
Who is sponsoring clinical trial NCT00141050?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.